biopharmaceutical company

Outlook Therapeutics Targets U.S. Launch of FDA-Approved LYTENAVA

ISELIN, N.J., August 14, 2026 Outlook Therapeutics, Inc. is advancing preparations for the U.S. commercial launch of LYTENAVA™ (bevacizumab-vikg)...

By cGxPwire Editor
August 15, 2026

Bio-Pharma

Kamada Strengthens Plasma Supply Business with $50M Deal

REHOVOT, Israel, and HOBOKEN, NJ | July 20, 2026 Kamada Ltd. announced a three-year plasma supply agreement valued at...

By cGxPwire Editor
July 21, 2026

Bio-Pharma

CorMedix Highlights Anti-Infective Strategy at JPM 2026

BERKELEY HEIGHTS, New Jersey | January 9, 2026 — CorMedix Therapeutics, a biopharmaceutical company focused on life-threatening infectious diseases,...

By cGxPwire Editor
January 12, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

biopharmaceutical company

Outlook Therapeutics Targets U.S. Launch of FDA-Approved LYTENAVA

Kamada Strengthens Plasma Supply Business with $50M Deal

CorMedix Highlights Anti-Infective Strategy at JPM 2026